Revolution Medicines (RVMD) Receivables (2020 - 2023)

Revolution Medicines' Receivables history runs 4 years deep, the most recent figure standing at $1.3 million for Q4 2023.

• In Q4 2023, Receivables fell 73.16% year-over-year to $1.3 million; the TTM figure through Dec 2023 stood at $1.3 million (down 73.16% YoY), while the FY2023 annual figure was $1.3 million, down 73.16% from the prior year.
• Receivables was $1.3 million for Q4 2023 at Revolution Medicines, up from $309000.0 in the prior quarter.
• In the past five years, Receivables ranged from a high of $12.8 million in Q4 2020 to a low of $309000.0 in Q3 2023.
• Historically, Receivables has averaged $5.3 million across 4 years, with a median of $5.4 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Receivables slipped 13.83% in 2022, then plunged 93.74% in 2023.
• A 4-year view of Receivables shows it stood at $12.8 million in 2020, then plunged by 53.63% to $5.9 million in 2021, then dropped by 21.18% to $4.7 million in 2022, then slumped by 73.16% to $1.3 million in 2023.
• The last three Receivables figures came in at $1.3 million (Q4 2023), $309000.0 (Q3 2023), and $2.5 million (Q2 2023), per Business Quant data.